A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)
This study was designed to evaluate the safety and efficacy of neoadjuvant and adjuvant atezolizumab in participants with resectable Non-Small Cell Lung Cancer (NSCLC). Neoadjuvant therapy consisted of two 21-day cycles with atezolizumab. Following surgery, adjuvant therapy consisted of up to 12 months of atezolizumab in participants who demonstrate clinical benefit with neoadjuvant therapy. All participants who undergo surgery entered a surveillance period, which consisted of standardized blood sample collection and Chest CT Scans, for up to 2 years. All participants were monitored for disease recurrence and survival for up to 3 years after last dose of study drug.
Checked against the public recordLast updated Sep 19, 2024 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Genentech, Inc.
- Interventions being studied
- Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Pathologically documented Stage IB, II, IIIA, or selected IIIB, including T3N2 or T4 (by size criteria, not by mediastinal invasion) NSCLC * Adequate pulmonary and cardiac function * Available biopsy of primary tumor with adequate samples * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Exclusion Criteria: * NSCLC that is clinically T4 by virtue of mediastinal organ invasion or Stage IIIB by virtue of N3 disease * Any prior therapy for lung cancer within 3 years. * Prior treatment with anti-PD-1 or PD-L1 therapies * History or risk of autoimmune disease
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- City of Hope Comprehensive Cancer CenterDuarte, California
- UCLA Cancer CenterSanta Monica, California
- University Of ColoradoAurora, Colorado
- Yale Cancer CenterNew Haven, Connecticut
- Moffitt Cancer CenterTampa, Florida
- Emory University; Winship Cancer InstituteAtlanta, Georgia
- Dana Farber Cancer Institute; Brigham and Womens HospitalBoston, Massachusetts
- Mass General/North Shore CancerDanvers, Massachusetts
- Karmanos Cancer Inst; Hematology/OncologyDetroit, Michigan
- Washington University; Wash Uni. Sch. Of MedSt Louis, Missouri
- Dartmouth Hitchcock Medical CenterLebanon, New Hampshire
- Memorial Sloan Kettering - MonmouthMiddletown, New Jersey
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 19, 2024. Always confirm current availability with the study team.